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The plasma-membrane monoamine transporters (MATs), including the serotonin (SERT),
norepinephrine (NET) and dopamine (DAT) transporters, serve a pivotal role in limiting
monoamine-mediated neurotransmission through the reuptake of their respective
monoamine neurotransmitters. The transporters are the main target of clinically used
psychostimulants and antidepressants. Despite the availability of several potent and
selective MAT substrates and inhibitors the continuing need for therapeutic drugs to treat
brain disorders involving aberrant monoamine signaling provides a compelling reason to
identify novel ways of targeting and modulating the MATs. Designing novel modulators of
MAT function have been limited by the lack of three dimensional structure information of
the individual MATs. However, crystal structures of LeuT, a bacterial homolog of MATs,
in a substrate-bound occluded, substrate-free outward-open, and an apo inward-open
state and also with competitive and non-competitive inhibitors have been determined. In
addition, several structures of the Drosophila DAT have also been resolved. Together
with computational modeling and experimental data gathered over the past decade,
these structures have dramatically advanced our understanding of several aspects of
SERT, NET, and DAT transporter function, including some of the molecular determinants
of ligand interaction at orthosteric substrate and inhibitor binding pockets. In addition
progress has been made in the understanding of how allosteric modulation of MAT
function can be achieved. Here we will review all the efforts up to date that has been
made through computational approaches employing structural models of MATs to design
small molecule modulators to the orthosteric and allosteric sites using virtual screening
techniques.
Keywords: dopamine transporter, modeling and simulations, monoamine transporters, norepinephrine transporter,
serotonin transporter, hybrid structure based screening, virtual screening
Introduction
The family of sodium coupled plasma membrane monoamine transporters (MATs) include the
serotonin (SERT), dopamine (DAT), and norepinephrine (NET) transporters (Torres et al., 2003;
Kristensen et al., 2011). They are critically involved in regulatingmonoaminergic neurotransmission
through the reuptake of their respective neurotransmitter. They are all expressed in the presynaptic
neuron fromwhich their respective monoamine neurotransmitter (MA) is synthesized and released.
As a consequenceMATmediated reuptake of MAs is also believed to be important for MA recycling
and repackaging in the presynaptic monoaminergic neuron (Torres et al., 2003). All MATs are
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pharmacological targets of some of the most psychoactive
compounds in clinical use. These include inhibitors such as
tricyclic antidepressants (TCAs), selective serotonin reuptake
inhibitors (SSRIs), and psychostimulants such as amphetamine
and cocaine.
Early Structure/Function Studies
The MATs are members of the neurotransmitter:sodium
symporter (NSS) SLC6 family of transporters that also include
GABA transporters (Kristensen et al., 2011). Immediately
upon the identification of the genes of the MATs and related
transporters within the NSS family it was realized that they were
12 transmembrane domain (TM) containing proteins. Early
structure function studies confirmed through biochemical assays
that the N- and C-termini of the proteins were intracellular
(Kristensen et al., 2011). Functional characterization also
established that they are sodium-dependent symporters utilizing
the sodium ion gradient established by sodium/potassium
ATPases to transport their respective substrates against their
gradients. The transporters are also dependent on extra-cellular
chloride, though the understanding of the role of chloride
in the transport process is limited (Kanner, 1989; Rudnick,
1998). The transport process is believed to proceed through a
classical alternating access mechanism with the transporter going
through several different conformations that include states in
which the substrates are occluded from the intracellular and
extracellular environment (Krishnamurthy et al., 2009; Penmatsa
and Gouaux, 2014). Expression of the transporters in Xenopus
oocytes established that substrate translocation is electrogenic
and involves the movement of sodium and chloride ions (Sonders
and Amara, 1996). Some of the ion fluxes are coupled to the
transport cycle but these currents are larger than predicted from
stoichiometric calculations. In addition uncoupled currents have
also been demonstrated that display similarities to an ion-channel
like flux. The early structure function studies pointed to TM1
as being critical for substrate interactions—in particular an
aspartate centrally located within TM1 (Kitayama et al., 1992;
Barker et al., 1999). Studies on inhibitor interaction also found
evidence for an important role for residues in TM1 and 3 (Barker
et al., 1998; Larsen et al., 2004). Though these studies provided
highly significant progress in the molecular understanding of
transporter function and ligand interactions they were limited by
the lack of high resolution three dimensional (3D) structures to
guide additional mechanistic studies.
Crystal Structures of LeuT
A dramatic change in our structural understanding of the MATs
occurred with the elucidation of the 3D structure of LeuT,
a bacterial leucine transporter homolog of the MATs. The
first structure that was elucidated was of LeuT bound to its
substrate leucine occluded from the extracellular and intracellular
environment (Yamashita et al., 2005). The structure also revealed
the location of two sodium ion binding sites. In this crystal
structure, the transporter was a homo-dimer and each monomer
consisted of 12 TMs with some TMs being discontinuous.
The protein consisted of an intriguing pseudo twofold axis of
symmetry formed by TM1–5 and TM6–10 respectively that can
be superimposed on each other. This intriguing novel fold, that
was unique at the time of elucidation has now been found in
several other unrelated transporter families and is therefore not
restricted to only the NSS family (Penmatsa and Gouaux, 2014).
The crystal structures also highlighted that domains TM1 and 6
and TM3 and 8 forms and defines the inner core translocation
pathway. This is in agreement with the structure/function studies
that were performed prior to the structure determinations that
demonstrated a role for TM1 and 3 in both substrate and
inhibitor interactions. The substrate leucine was occluded from
the extracellular and intracellular space by a gate structure formed
by both ionic and hydrophobic interactions between specific
residues. Following the initial publication of the LeuT transporter
in the out-ward facing substrate-occluded conformation several
other conformational states of this transporter have now been
elucidated. These structures include structures with a non-
competitive TCA bound to an extracellular vestibule above the
proposed extracellular gate (Singh et al., 2007; Zhou et al., 2007)
and a structure of a competitive inhibitor tryptophan bound to a
forced open conformation of LeuT (Singh et al., 2008). Finally,
structures have been elucidated of LeuT in substrate-free open
and inward-facing conformations (Krishnamurthy and Gouaux,
2012).
Crystal Structure of Drosophila DAT
A further major step forward in our structural understanding
of MAT function was achieved by the elucidation of an actual
MAT as theDrosophilaDATwas crystalized and a high resolution
structure was obtained (Penmatsa et al., 2013). This structure also
provided support for the use of LeuT structures as models for
MAT studies as it was found that the DAT structure was similar to
LeuT. Some minor but interesting differences were found in the
C-terminal part of the protein as a kink was observed in TM12
and the intracellular C-terminus was found to form a helix that
interacted with the first intracellular loop. In support of previous
biochemical studies (Hong and Amara, 2010) the DAT structure
also revealed specific interactions withmembrane lipids including
cholesterol. Finally, additionalDrosophila structures have recently
been determined revealing substrate, psychostimulant (Wang
et al., 2015), and antidepressant binding sites (Penmatsa et al.,
2015).
Functional Studies Based on MAT Models
With the availability of the bacterial LeuT and Drosophila DAT
structures, several seminal modeling and structure functions
studies based on the crystal structures have now enabled a
much clearer understanding of several aspects of mammalian
MAT function. A review by Manepalli et al. (2012), highlighted
the various conformational states of LeuT and the utility of
these crystal structures to understand the structure-function and
dynamics of SERT, DAT and NET. The models proposed based
on the LeuT crystal structures were used to develop hypothesis
to understand the role of these MATs in normal and disease
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states (Vaughan and Foster, 2013). These models of MATs were
instrumental in identifying the various functional sites including
the substrate, inhibitor, ion, allosteric binding sites and to design
selective modulators as described below.
Substrate Binding Site
For all three MATs, modeling studies and structure/functions
studies suggest that there is significant overlap between the leucine
binding site in LeuT referred to as S1 and themonoamine binding
sites in the MATs. In fact, several of the residues that form the
binding site are conserved. Extensive structure function studies
have been carried out on SERT and DAT that confirmed the
importance of an aspartate in TM1 (Beuming et al., 2008; Celik
et al., 2008; Indarte et al., 2008; Wang et al., 2012; Koldso et al.,
2013). In addition, these studies also revealed the involvement
of residues in TM3 and 8 for the interaction with serotonin
(Celik et al., 2008). For DAT, the corresponding residues that
were engaged in the interaction with dopamine were identified
through modeling and experimental studies (Beuming et al.,
2008). Furthermore, though difficult to verify experimentally,
these studies also demonstrated an interaction between the
substrates and the backbone carbonyls of the unwound region of
TM1 and 6.
Ion Binding Site
It is well established that all MATs are sodium dependent utilizing
the gradient set up by the sodium/potassium ATPases to drive the
transport of their individual substrates (Kanner, 1989; Rudnick,
1998). The mechanism of the coupling of sodium flux and
substrate uptake is not well established. It was therefore highly
significant that the LeuT structures revealed some information
regarding the interaction of LeuT with sodium as two sodium
ions were found to be co-crystalized. One of the sodium ions
was found to interact directly with the substrate leucine and
supports the hypothesis of direct coupling between sodium and
substrate binding. Because the residues found to coordinate this
central sodium ion in LeuT are conserved among the SLC6
transporters, it also suggests a common mechanism for all
transporters in their engagement of the sodium gradients to drive
substrate transport. Providing experimental support to explore
mechanistic questions regarding the role of the sodium ions
in facilitating transport are made difficult given their central
and conserved role. A recent biophysical modeling study used
extensive simulations to explore the conformational changes that
occur following sodium binding. This study revealed a role for
sodium in facilitating the closing of the extracellular gate formed
by a central phenylalanine and the tilting of central TMs to
enable the inward movement of the substrate (Zomot et al.,
2015).
Different from the sodium dependent LeuT, all MATs are
sodium and chloride dependent. Therefore there was no obvious
information in the LeuT structures regarding the role of
chloride inMAT transporter function. However, two independent
studies did take advantage of the LeuT structure to identify
a potential site of chloride interaction in the sodium and
chloride dependent MATs. Comparing the sequence alignments
of chloride dependent and independent NSS transporters, a
negatively charged glutamate residue in TM7 was identified
in the chloride independent transporters and it was suggested
this negative charge provided by a glutamate residue has the
same function as the negative charge provided by the chloride
ion (Forrest et al., 2007; Zomot et al., 2007). Furthermore,
the LeuT structure put this charged residue close to one
of the sodium ion binding sites suggesting that the negative
charge is directly linked to and cooperates with the sodium
in all NSS transporters to facilitate transport. The role of this
residue was further investigated experimentally by replacing the
corresponding residue in chloride dependent transporters with
glutamate resulting in chloride independent transporters and vice
versa (Zomot et al., 2007).
Gates
The first LeuT structure was in a conformation of the transporter
with the substrate occluded from both the extra- and intra-
cellular space (Yamashita et al., 2005). It therefore immediately
suggested the location of protein domains involved in shielding
and occluding the substrate during translocation. These domains
are different from classical gates associated with ion-channels
but the term “gate” will be used to discuss these domains in
this review. In the out-ward facing conformation, an extracellular
vestibule is positioned above the occluded substrate that provides
access to the extracellular environment. At the bottom of this
vestibule a domain forms the gate that occludes the substrate.
This domain is formed by a conserved pair of charged residues
forming a putative salt bridge (Pedersen et al., 2014) and further
down, immediately below an additional seal is formed by a
structure of two aromatic residues. The access to the occluded
substrate binding site from the intracellular environment is
hindered by a more complex thicker domain formed by TMs
1, 6, and 8. Another pair of charged residues is located
below this domain forming an additional salt bridge that in
MATs have been experimentally examined and shown to affect
the conformational states of the transporters (Kniazeff et al.,
2008).
Inhibitor Binding Site
Most known inhibitors of MATs display competitive inhibition
characteristics and a significant overlap between the substrate
and inhibitor binding sites is therefore expected. Several extensive
modeling studies have examined the site of interaction between
antidepressants including TCAs and SSRIs with SERT and NET
(Andersen et al., 2009, 2010, 2011, 2014; Koldso et al., 2010;
Sinning et al., 2010; Severinsen et al., 2012, 2014; Wang et al.,
2012) and psychostimulants including cocaine and its analogs
with DAT (Beuming et al., 2008; Indarte et al., 2008; Loland et al.,
2008; Bisgaard et al., 2011). Not surprisingly, these studies point
to similar structures at the S1 site that are involved in substrate
binding to also be important for interactions with all these above
ligands.
Identification and characterization of the above determined
functional sites serves as an important step toward designing
small molecule modulators to treat disorders associated
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with the dysfunction of MATs. In the past, most drugs were
discovered either through historical knowledge of natural
products, serendipity, repurposing or through screening of
small libraries of compounds using in vitro high throughput
screening techniques. Although these methods yield useful lead
compounds, the process is self-limiting, expensive and tedious.
Virtual screening techniques have bridged the gap in terms of
time and efforts to improve the early discovery process and to
yield quality lead molecules.
Virtual Screening and Ligand Design
Virtual Screening techniques have gained recognition as a
useful and economical tool to screen millions of compounds
in early drug discovery. Virtual screening in combination with
in vitro and in vivo validation has the potential to improve the
chances of finding better lead compounds. Some well-known
examples of drugs that were designed using virtual screening
techniques include the HIV integrase inhibitor raltegravir which
was approved by FDA in 2007 to treat AIDS (Perryman et al.,
2010). Tirofiban—a GP IIb/IIIa antagonist with anticoagulant
properties has been used to treat myocardial infarction and
was designed using an in silico virtual screening scheme and
further optimized for drug like properties (Hartman et al., 1992).
Most recently, we have developed novel antimalarial pyrazole
amide class of compounds that disrupt the ion homeostasis
in the malaria parasite leading to its death (Vaidya et al.,
2014). This series of compounds were identified using our
platform screening technology called the hybrid structure based
(HSB) method (Kortagere et al., 2010). The fast killing rate
induced by low picomolar concentrations of the pyrazole amide
molecule alongwith its drug-like properties are key differentiators
that has led to its inclusion in the discovery pipeline by
Medicines for Malaria Venture (Vaidya et al., 2014). Other
successful lead compounds that were designed using the HSB
method include an atypical dopamine D3 receptor agonist
that has shown significant promise in treating L-dopa induced
dyskinesias and motor impairment in Parkinson’s disease in
rodentmodels (Kuzhikandathil and Kortagere, 2012; Simms et al.,
2015). These and other successful stories reported in literature
(Geyer et al., 2005; Agarwal and Fishwick, 2010) have provided
credibility to the use of virtual screening techniques in drug
discovery.
Structural information for most members of the human SLC6
family is unavailable, however, computational modeling and
virtual screening has contributed immensely to designing new
inhibitors. These include SSRIs (Nolan et al., 2011), selective
NET inhibitors (Schlessinger et al., 2011), triple uptake inhibitors
(Kim et al., 2009), and most recently allosteric modulators of
transporter function (Kortagere et al., 2013). Virtual screening
has been broadly classified into ligand-based and structure-
based methods (Kortagere et al., 2012), but the use of hybrid
methods such as the hybrid structure-based method of screening
have also gained importance (Kortagere and Welsh, 2006).
Ligand based methods have used well known ligands to build
quantitative structure activity relationship (QSAR) models to
design congeneric series of MAT inhibitors (Schlessinger et al.,
2011). Most significant among them were the 3D-QSAR and
comparative molecular field analysis (CoMFA) methods that
were used to derive several high affinity ligands primarily
for DAT (Kulkarni et al., 2004; Christensen et al., 2007) and
some triple uptake inhibitors that had nearly equal affinity
for all three MATs. Some studies also employed ligand based
pharmacophore methods to derive high affinity molecules by
using the pharmacophores generated out of GBR-12909 and
tropane analogs and screening the NCI database (MacDougall
and Griffith, 2008). These early QSAR based screening models
were well suited to design ligands due to lack of crystal
structures of the human NSS/SLC6 protein family. However,
crystal structures of LeuT from the bacterium Aquifex aeolicus
in various states including outward open form, occluded form,
in complex with various other amino acids (Singh et al., 2008),
sugars (Quick et al., 2009), and drug molecules (Zhou et al.,
2007, 2009) have provided suitable templates for modeling
the corresponding conformational states of the human MATs.
Structure based methods including receptor pharmacophore
models and molecular docking methods have taken advantage
of these LeuT based models for virtual screening of MAT
inhibitors.
Screening Inhibitors to Orthosteric S1
Binding Site
All MATs are considered to have a well-conserved primary
binding pocket commonly referred to as the S1 pocket. The S1
pocket is the Leucine binding site derived from the LeuT crystal
structures and was also validated using biochemical mutation
studies in other MATs as described above for the substrate and
inhibitor binding site. The S1 pocket (Figure 1) is lined by
residues N21, A22, G24, L25, G26, Y108, I359, F253, S256, F259,
S355 in the LeuT crystal structure bound to Leucine (pdb code:
3F3E; Singh et al., 2008). Virtual screening techniques using
receptor pharmacophore models of the SERT S1 pocket has led
to the design of novel SSRIs and antidepressant molecules (Nolan
et al., 2011, 2014). A study by Schlessinger et al. (2011) utilized
molecular docking and virtual screening techniques to screen the
FIGURE 1 | Crystal structure of LeuT is shown in cartoon format and
colored orange. The binding site residues forming the S1 pocket (Singh
et al., 2008; see text for details) are shown as licorice sticks and colored atom
t ype (C-cyan, N-blue, O-red).
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KEGG DRUGs (Kanehisa et al., 2010) database to design novel
NET ligands binding to the S1 site of the transporter.
Allosteric Binding Sites
For several decades a puzzling activity has been noted for some
ligand interactions with SERT. It was demonstrated that when
performing dissociation studies some ligands would have the
rather unexpected effect of slowing the dissociation of other
ligands (Chen et al., 2005; Neubauer et al., 2006; Zhong et al.,
2012). It was speculated that this was caused by these ligands
interacting with a second site that acted through an allosteric
mechanism to affect the primary central S1 ligand binding site
described above that overlaps with the substrate binding site.
Structures with TCAs bound to LeuT exist and have provided
a mechanism for these observations (Singh et al., 2007; Zhou
et al., 2007). It is important to note that TCAs inhibit LeuT
non-competitively and significant differences must exist in the
low affinity interaction between TCAs and LeuT compared with
the high affinity competitive interaction of TCAs with SERT.
As a consequence, even though these structures reveal a high
resolution picture of a TCA binding site in LeuT it is not likely
that this site is similar to the high affinity TCA binding site in
SERT. Indeed, in the LeuT structure co-crystalized with TCA,
the TCA was found to be located above the extracellular gate-
like structures that were described above to occlude the substrate
binding site from the extracellular environment and therefore, also
different from the substrate/inhibitor binding site (S1) described
above that has been validated experimentally. In further structural
support of this notion that the high affinity inhibitor binding
site in MATs overlap with the central substrate binding site, it
was found in all the most recent structures of the antidepressant
sensitiveDrosophilaDAT that all examined inhibitors were bound
to central structures overlapping with the dopamine binding site
(Penmatsa et al., 2013, 2015; Wang et al., 2015). On the other
hand, the observation of TCA binding to LeuT at a secondary
site was tempting to be taken as evidence for an allosteric site and
a recent study has explored how this secondary TCA site could
relate to the allosteric interaction of some SERT ligands (Plenge
et al., 2012). The study mutated residues in similar structures in
the extracellular vestibule of mammalian SERT that was found
to interact with TCA in LeuT. This reduced the above described
allosteric effects on ligand dissociation from the primary substrate
and inhibitor binding site located more centrally in SERT and
supports the hypothesis that SERT ligands can modulate function
through interactions with secondary sites.
The TCA binding pocket in LeuT [also referred to as the
S2 site in some studies (Quick et al., 2009)] has been further
characterized functionally as an allosteric site to the orthosteric
binding site. The TCA binding pocket is proximal to the S1 site
and is networked through a series of hydrogen bonds, therefore,
conformational changes induced by TCAs at this site affect the
translocation pathway. The TCA binding pocket (Figure 2) in
the LeuT structure is formed by residues from TM1 (L25, L29,
R30, V33, E37), TM3 (Y107, I111, W114), TM6 (F253), and
TM10 (K398, L400, D401, D404) domains and is well conserved
across all MATs (Nolan et al., 2011). Finally, a novel class of MAT
FIGURE 2 | Crystal structure of LeuT is represented in cartoon format
and colored orange. The binding site residues forming the TCA/S2 pocket
(Nolan et al., 2011; see text for details) are shown as licorice sticks and
colored atom type (C-cyan, N-blue, O-red). The TCA pocket is adjacent to the
S1 pocket in the crystal structure.
FIGURE 3 | Three-dimensional structural model of hSERT is
represented in cartoon format and colored orange. The binding site
residues forming the A1 allosteric pocket (Kortagere et al., 2013; see text for
details) are shown as licorice sticks and colored atom type (C-cyan, N-blue,
O-red). The allosteric pocket is distinct from both the S1 and the TCA/S2
pockets and is positioned close to the extracellular region.
modulators has been isolated from a marine Conus marmoreus
snail. The Chi-conotoxin was found to specifically inhibit NET
function in a non-competitively manner and structure/function
studies suggested an interaction between this peptide and the
extracellular vestibule (Bryan-Lluka et al., 2003; Paczkowski et al.,
2007). Taken together, these studies opens up the possibility
of targeting MATs in novel ways as ligands that specifically
interact with structures outside the substrate binding site can
have allosteric modulatory effects on MAT/ligand interactions
and MAT function.
A few studies have directly targeted the TCA/S2 pocket
for screening novel ligands. The study by Indarte et al.
(2008) screened a library of 140,000 molecules against the
TCA/S2 binding pocket of DAT to derive novel chemotypes
that could competitively inhibit the binding of cocaine to the
S1 site. In a similar study on the TCA/S2 binding pocket
of SERT, virtual screening of the ZINC database led to the
design of two novel SERT ligands (Manepalli et al., 2011).
Improvements in computational resources and the availability
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of large combinatorial chemistry libraries from various vendors
has also led to improvements in the screening technologies. A
study by Gabrielsen et al. (2014) used a combined library of
3.24 million molecules to design novel SERT ligands using a
variety of in silico techniques including 2D and 3D similarity, 3D
pharmacophore and flexible docking methods. All these success
stories suggest that structure based virtual screening is a powerful
tool to design small molecule inhibitors to MATs, despite having
no direct structural information on any of the MATs (except for
the very recent Drosophila DAT) and a template identity less than
30%.
Other Allosteric Pockets
In addition to the well-known S1 and the allosteric TCA/S2
binding pockets of MATs, we have utilized molecular dynamics
simulations and comparative genomics techniques to identify
allosteric pockets outside the translocation pathway of MATs
that when engaged can specifically modulate the binding of
known transporter ligands (Kortagere et al., 2013). The hybrid
structure based screening platform (Kortagere and Welsh, 2006)
was used to design these allosteric modulators. Beginning with
the 3D model of SERT structure immersed in a POPCmembrane
model, the HSB method incorporates dynamic conformational
changes to screen for allosteric pockets. One such pocket that
is conserved across all MATs, is a pocket (Figure 3) formed by
TM1, TM6, TM10, TM11, and EL6 domains that we refer to
as A1 and that is lined by residues Q111, N112, I327, D328,
A331, Q332, K490, E494, R564, Y568, and Y572 in SERT. A
four point receptor pharmacophore was developed using the
residues D328, K490, E494 and Y568. The pharmacophore was
used to screen a custom library of 3 million compounds leading
to the design of ATM7—an allosteric modulator of SERT that
binds to this novel site and elicits a conformational change that
results in the facilitation of serotonin uptake and potentiates
MDMA-elicited reversed transport. Among other compounds
discovered through this screen are compounds that interact
at novel A1 allosteric site and modulate the interaction of
MATs with classical inhibitors including antidepressants and
psychostimulants.
Conclusion
Monoamine transporters play an important role in the brain
by actively translocating MAs thereby modulating numerous
physiological processes that are regulated by MAs. In addition,
these plasma membrane transporters bind to a variety of
compounds that achieve their effect through the inhibition of the
monoamine uptake. These compounds include psychostimulant
drugs and antidepressants that are therapeutically relevant and
illicit drugs such as cocaine andmethamphetamine. Dysfunctions
of MATs are implicated in a variety of disorders including
depression, mania, addiction and cognition suggesting their
key role as therapeutic targets. Despite advances in protein
crystallography techniques, 3D structure of only a few members
of the NSS family that includeMATs are available. Computational
techniques including homology modeling, molecular dynamics
simulations and virtual screening techniques have resulted in
a better understanding of the structure-activity relationships of
various inhibitors and substrates with MATs and the design
of novel chemotypes to the orthosteric and allosteric pockets.
Improvements in screening technologies and the availability of
larger chemical libraries have also significantly improved the
quality of these ligands resulting in highly efficacious and sub-
type selective ligands. Since MATs can be significant targets for
both disease modifying and symptomatic treatments of many
psychiatric diseases, novel chemotypes that can uniquely target
these transporters with improved side effect profiles will be highly
desirable.
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